



November 12, 2024

Company name: TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi, Chief Executive Officer  
(Securities code 4891; Growth Market)

## Notice Concerning the Patent for which TMS is granted license (US) to use

TMS Co., Ltd. (the “Company”) announces today that the patent has been granted in the U.S with regard to the patent application that the Company had filed jointly with Showa University on March 23, 2018 in Japan and later for international application on February 26, 2019 (the “Patent Family”).

This patent is a method-of-use invention related to a new treatment for acute kidney injury using various compounds including TMS-008, which the Company is currently developing. The Company's patent interests were originally transferred to Biogen under the option agreement therewith, and have been transferred to CORXEL Pharmaceuticals Inc., which has taken over the option agreement from Biogen. The Company has obtained a license from CORXEL to use CORXEL's interests in the Patent Family worldwide.

The Patent Family has been granted in Japan in October 2023 and in China in December of the same year.

### Patent Summary

Title of invention : Drug and Method of Treating or Preventing Renal Disease Using Drug  
International Publication Number : WO2019/181388  
Patent number in the US : Patent No. 12138244  
Issue date : November. 12 2024  
Assignee : Ji Xing Pharmaceuticals Hong Kong Limited, Showa University

This matter will not have a significant impact on the financial results for the fiscal year ending on February 28, 2025.

### About TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (*Stachybotrys Microspora* Triprenyl Phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/>.

Investor and Media Contact:

[ir@tms-japan.co.jp](mailto:ir@tms-japan.co.jp)

End